LTRN Profile
Lantern Pharma Inc. is a clinical-stage biotechnology company that leverages artificial intelligence (AI), machine learning, and genomic data to enhance and expedite the drug development process. The company focuses on developing innovative cancer therapies and utilizes its proprietary technology platform to identify and advance promising drug candidates. Its lead therapeutic candidate, LP-100, is currently undergoing Phase II clinical trials for the treatment of metastatic, castration-resistant prostate cancer. This advanced drug is designed to target specific pathways involved in prostate cancer progression, aiming to offer a new treatment option for patients with advanced disease.
In addition to LP-100, Lantern Pharma is advancing LP-300, a drug being developed as a combination therapy for non-smokers or never-smokers with non-small cell lung cancer (NSCLC) adenocarcinoma. This candidate aims to address a significant unmet need in the NSCLC treatment landscape, targeting specific molecular profiles associated with the disease. The company is also advancing LP-184, a preclinical drug candidate that functions as an alkylating agent to induce DNA damage in cancer cells. LP-184 targets tumors with overexpressed biomarkers or mutations in DNA repair pathways, potentially offering a targeted approach to overcoming cancer resistance mechanisms.
Lantern Pharma’s research and development efforts are supported by its proprietary AI platform, RADR. This platform utilizes big data analytics and machine learning to integrate and analyze complex molecular data, enabling the identification of potential drug candidates and biomarkers. The RADR platform is central to Lantern’s strategy, driving the discovery and development of targeted therapies by combining extensive genomic and clinical data to optimize drug development and patient outcomes.
Founded in 2013 and headquartered in Dallas, Texas, Lantern Pharma is at the forefront of utilizing advanced technologies to revolutionize cancer treatment. The company’s commitment to integrating AI and machine learning with drug discovery and development underscores its dedication to addressing critical needs in oncology. As Lantern Pharma advances its clinical programs and continues to refine its therapeutic pipeline, it aims to make significant contributions to the treatment of various cancer types and improve patient care through innovative therapies.
|
